---
{"dg-publish":true,"permalink":"/USMLE/Infective disease/Antiviral therapy/"}
---

Left part is for [[USMLE/Infective disease/Human immunodeficiency virus\|HIV]], right part is for other virus.![Pasted image 20240114163028.png](/img/user/appendix/Pasted%20image%2020240114163028.png)
>[!tip] 
>See [[USMLE/Infective disease/HIV therapy\|HIV therapy]] for NRTIs and [[USMLE/Infective disease/HIV therapy\|NNRTIs]]...

# Anti-herpesvirus Agents

*   **Acyclovir, Valacyclovir, Famciclovir**
    *   **Mechanism:** Guanosine analogs. Require phosphorylation by viral **thymidine kinase** (TK) for activation → inhibit viral DNA polymerase → chain termination. Valacyclovir (prodrug of acyclovir) and famciclovir have better oral bioavailability.
    *   **Clinical Use:** [[USMLE/Infective disease/Herpesviruses\|HSV]]-1, [[USMLE/Infective disease/Herpesviruses\|HSV]]-2, [[USMLE/Infective disease/Shingles\|VZV]]. Ineffective against [[USMLE/Infective disease/Cytomegalovirus infection\|CMV]] and [[USMLE/Infective disease/Infectious mononucleosis\|EBV]] due to different or minimal TK activity.
    *   **Adverse Effects:** **Obstructive crystalline nephropathy**, neurotoxicity (confusion, hallucinations). Preventable with adequate hydration.
    *   **Resistance:** Mutated viral TK.![Pasted image 20240207162621.png](/img/user/appendix/Pasted%20image%2020240207162621.png)![Pasted image 20231222091724.png](/img/user/appendix/Pasted%20image%2020231222091724.png)

*   **Ganciclovir, Valganciclovir**
    *   **Mechanism:** Guanosine analog. Requires phosphorylation by [[USMLE/Infective disease/Cytomegalovirus infection\|CMV]]-specific protein kinase **UL97** for activation → inhibits viral DNA polymerase.
    *   **Clinical Use:** **[[USMLE/Infective disease/Cytomegalovirus infection\|CMV]]**, especially retinitis in immunocompromised patients.
    *   **Adverse Effects:** **Bone marrow suppression** (leukopenia, [[USMLE/Blood/Neutropenia\|neutropenia]], thrombocytopenia), nephrotoxicity.

*   **Foscarnet**
    *   **Mechanism:** Pyrophosphate analog. <span style="background:rgba(240, 200, 0, 0.2)">Directly inhibits viral DNA/[[USMLE/Biochemistry/RNA polymerases\|RNA polymerase]] and [[USMLE/Infective disease/Human immunodeficiency virus\|HIV]] reverse transcriptase **without requiring kinase activation**.</span>
    *   **Clinical Use:** [[USMLE/Infective disease/Cytomegalovirus infection\|CMV]] retinitis in immunocompromised patients; acyclovir-resistant [[USMLE/Infective disease/Herpesviruses\|HSV]]/[[USMLE/Infective disease/Shingles\|VZV]].
    *   **Adverse Effects:** **Nephrotoxicity**, electrolyte abnormalities (hypo/[[USMLE/Cardiology/Hypercalcemia\|hypercalcemia]], hypo/hyperphosphatemia, [[USMLE/Cardiology/Hypokalemia\|hypokalemia]], [[USMLE/Renal/Hypomagnesemia\|hypomagnesemia]]) → can cause [[USMLE/Neurology/Seizures and epilepsy\|seizures]].![Pasted image 20231222093206.png](/img/user/appendix/Pasted%20image%2020231222093206.png)

*   **Cidofovir**
    *   **Mechanism:** Cytosine nucleotide analog. Directly inhibits viral DNA polymerase, **does not require viral kinase activation**.
    *   **Clinical Use:** CMV retinitis in HIV patients.
    *   **Adverse Effects:** **Nephrotoxicity** (severe). Co-administer with **probenecid** and IV saline to decrease toxicity.

# Anti-influenza Agents

*   **Neuraminidase Inhibitors (Oseltamivir, Zanamivir)**
    *   **Mechanism:** Inhibit [[USMLE/Infective disease/Influenza\|influenza]] neuraminidase, <span style="background:rgba(240, 200, 0, 0.2)">preventing the release of progeny virions from infected cells.</span> Active against influenza A and B.
    *   **Clinical Use:** Treatment and prophylaxis of influenza. Must be given within **48 hours** of symptom onset for maximal benefit.
    *   **Adverse Effects:** Oseltamivir: GI upset. Zanamivir: bronchospasm (avoid in asthma/COPD).![Pasted image 20231222091013.png](/img/user/appendix/Pasted%20image%2020231222091013.png)

*   **Adamantanes (Amantadine, Rimantadine)**
    *   **Mechanism:** Block the M2 proton channel, inhibiting viral uncoating.
    *   **Clinical Use:** Limited due to widespread resistance among influenza A strains. Not active against influenza B.
    *   **Adverse Effects:** CNS effects (ataxia, dizziness, slurred speech).

# Anti-Hepatitis B & C Agents

*   **Hepatitis B (HBV) Tx**
    *   **Tenofovir, Entecavir, Lamivudine:** Nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Inhibit HBV DNA polymerase. Tenofovir and Entecavir are first-line due to low resistance rates.
    *   **[[USMLE/Biochemistry/Interferons and Tumor necrosis factor\|Interferon]]-alfa (IFN-α):** Immunomodulatory effects. Used in younger patients with less advanced disease. Side effects include flu-like symptoms, depression, and autoimmune disorders.

*   **[[USMLE/GI/Hepatitis C\|Hepatitis C]] (HCV) Tx - Direct-Acting Antivirals (DAAs)**
    *   **NS3/4A Protease Inhibitors (-previr; e.g., Glecaprevir):** Inhibit the viral protease responsible for cleaving polyproteins.
    *   **NS5A Inhibitors (-asvir; e.g., Ledipasvir, Velpatasvir):** Inhibit NS5A, a phosphoprotein essential for viral replication and assembly.
    *   **NS5B [[USMLE/Biochemistry/RNA polymerases\|RNA Polymerase]] Inhibitors (-buvir; e.g., Sofosbuvir):** Inhibit the viral RNA-dependent RNA polymerase.
    *   **Management:** Typically treated with a combination of 2-3 DAAs for >90% cure rate with minimal side effects.
    *   **Ribavirin:** Guanosine analog, inhibits viral RNA synthesis. Used in combination with other agents. **Adverse effects:** [[USMLE/Blood/Hemolytic anemia\|Hemolytic anemia]], severe teratogen.